Aaron Ray

Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF), a developer of cannabinoid-based medicines, will conduct FDA Phase 2 and Phase 3 clinical trials for its HOPE-1 treatment of Autism Spectrum Disorder (ASD). Cantheon Capital LLC agreed to provide an initial $8.6 million in funding to Zelira to...

Psychedelics biopharma company Lobe Sciences Ltd. (OTCQB: LOBEF) signed a deal with Cantheon Capital, a development of cannabinoids and psychedelic drugs supporter, for aggregate proceeds to the company of up to $1.5 million for an annual term with a 15% interest. Funding for...